SNN vs ZBH: Smith & Nephew vs Zimmer Biomet Stock Comparison: AI Score, Valuation, Performance and Upside
Smith & Nephew and Zimmer Biomet are both mid-sized orthopedic medtech companies competing against Stryker and J&J for joint replacement and robotic surgery market share. Both have underperformed larger peers in recent years; both have robotic surgery platforms facing an uphill battle against Stryker Mako's installed base lead.
SNN vs ZBH is two orthopedic medtech challengers competing to close the gap with Stryker and J&J — Smith & Nephew wins if wound management provides earnings diversification while CORI gains share; Zimmer Biomet wins if ROSA robotic surgery captures meaningful knee replacement market share.
ZBH holds the edge across 3 of 5 key metrics in this comparison. ZBH leads on both 1-year return (-5.03%) and forward P/E quality (11.13x vs 12.08x for SNN), a relatively favorable combination of momentum and valuation. ZBH leads on both revenue growth (4.80%) and operating margin (17.96%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for SNN (+11.11%) than for ZBH (+6.60%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- want orthopedic medtech exposure diversified across implants, sports medicine, and wound management
- value Smith & Nephew's wound care segment as a recurring consumable revenue driver
- prefer a UK-based medtech ADR at a lower valuation than US-listed peers
- believe CORI robotics can gain traction against Stryker Mako over time
- prefer US-listed orthopedic medtech focused on knee and hip reconstruction
- believe ROSA robotic surgery can close the gap with Stryker Mako's installed base
- value Zimmer Biomet's dental segment as an additional orthopedic-adjacent revenue diversifier
- are comfortable with operational restructuring risk in exchange for potential margin improvement
| Metric | SNN | ZBH |
|---|---|---|
| AI scorei | 36.3 | 26.7 |
| AI ranki | #2486 | #2418 |
| Latest closei | $29.09 | $94.38 |
| 1M returni | +5.09% | -4.10% |
| 3M returni | -6.29% | +0.67% |
| 6M returni | -12.99% | -0.42% |
| 1Y returni | -15.52% | -5.03% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | SNN | ZBH |
|---|---|---|
| 1Y ago | $8.68K (-13.2%) started 2025-10-15 | $9.45K (-5.5%) started 2025-10-16 |
| 5Y ago | $10.87K (+8.7%) started 2021-10-15 | $7.1K (-29.0%) started 2021-10-18 |
| 10Y ago | $15.7K (+57.0%) started 2016-10-17 | $8.8K (-12.0%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | SNN | ZBH |
|---|---|---|
| Market capi | $12.17B | $19.25B |
| Trailing P/Ei | 19.79 | 24.49 |
| Forward P/Ei | 12.08 | 11.13 |
| Price/Salesi | 1.93 | 2.37 |
| EV/Revenuei | 10.31 | 3.10 |
| Analyst targeti | $32.32 | $107.57 |
| Target upsidei | +11.11% | +6.60% |
| Metric | SNN | ZBH |
|---|---|---|
| Revenue growthi | 4.60% | 4.80% |
| Earnings growthi | 5.70% | 33.80% |
| EPS growthi | +5.70% | +33.80% |
| FCF margini | +16.81% | +12.82% |
| Operating margini | 14.47% | 17.96% |
| Profit margini | 10.08% | 9.48% |
| ROIC proxyi | 11.85% | 6.41% |
| Return on equityi | 11.85% | 6.41% |
| Dividend yieldi | 2.73% | 0.95% |
| Payout ratioi | 53.20% | 23.30% |
| Dividend growth streaki | 1 yr | No increase yet |
| Betai | 0.67 | 0.46 |
| Debt/equityi | 73.07 | 60.17 |
| Current ratioi | 2.14 | 1.69 |
| Quick ratioi | 1.11 | 0.74 |
Over the past year, SNN and ZBH have moved moderately in the same direction (correlation of 0.48), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | SNN | ZBH |
|---|---|---|---|
| 1Y | Growthi | -15.52% | -5.54% |
| CAGRi | -15.53% | -5.55% | |
| Volatilityi | 28.16% | 32.48% | |
| Sharpe ratioi | -0.62 | -0.15 | |
| Sortino ratioi | -0.80 | -0.19 | |
| Max drawdowni | 27.41% | 23.47% | |
| Current drawdowni | 19.61% | 9.23% | |
| Avg drawdowni | 13.64% | 11.52% | |
| Ulcer Indexi | 15.18% | 12.60% | |
| Max daily dropi | 11.72% | 15.15% | |
| Max wkly dropi | 10.10% | 14.23% | |
| 5Y | Growthi | -5.87% | -31.00% |
| CAGRi | -1.20% | -7.16% | |
| Volatilityi | 27.46% | 27.16% | |
| Sharpe ratioi | -0.07 | -0.30 | |
| Sortino ratioi | -0.10 | -0.40 | |
| Max drawdowni | 40.07% | 44.52% | |
| Current drawdowni | 22.15% | 34.21% | |
| Avg drawdowni | 18.53% | 23.40% | |
| Ulcer Indexi | 20.46% | 25.35% | |
| Max daily dropi | 13.03% | 15.15% | |
| Max wkly dropi | 15.15% | 14.23% | |
| 10Y | Growthi | +21.08% | -17.88% |
| CAGRi | +1.93% | -1.95% | |
| Volatilityi | 27.04% | 28.80% | |
| Sharpe ratioi | 0.04 | -0.08 | |
| Sortino ratioi | 0.06 | -0.11 | |
| Max drawdowni | 55.06% | 52.63% | |
| Current drawdowni | 32.75% | 43.82% | |
| Avg drawdowni | 23.11% | 22.56% | |
| Ulcer Indexi | 28.19% | 26.89% | |
| Max daily dropi | 13.75% | 15.15% | |
| Max wkly dropi | 29.62% | 27.48% |
| Category | SNN | ZBH |
|---|---|---|
| Company | Smith & Nephew plc | Zimmer Biomet Holdings, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | Global medtech company with orthopedics (knee, hip implants), sports medicine (arthroscopy), and advanced wound management. Smith & Nephew is headquartered in the UK and trades as an ADR on the NYSE. | Global orthopedic implant and surgery company focused on knee and hip reconstruction, spine surgery, and dental implants. Zimmer Biomet's ROSA robotic surgery platform competes with Stryker's Mako. |
| Investor focus | Orthopedic procedure volume recovery, CORI robotic surgery system adoption, wound management innovation, and operational margin improvement. | ROSA robot adoption, orthopedic procedure volume, international revenue growth, and margin improvement after operational restructuring. |
- Diversified across three segments — orthopedics, sports medicine, and wound management — providing revenue resilience
- CORI robotic surgery system competes in the fast-growing robot-assisted orthopedic surgery market
- Advanced wound management is a differentiated, high-margin segment with recurring consumable revenue
- ROSA robotic surgery platform is gaining share in the robot-assisted knee replacement market
- Strong brand presence in knee and hip reconstruction in the US and Europe
- Dental segment diversification provides revenue outside core orthopedics
- Smith & Nephew has lagged peers in orthopedic revenue growth and has undergone multiple management changes
- CORI adoption is behind Stryker's Mako and J&J's Velys in installed base
- UK-listed company with ADR means currency fluctuations affect USD-reported results
- Zimmer Biomet has lagged Stryker's Mako in robotic surgery market share — a critical competitive battle
- Restructuring costs and operational complexity have weighed on margins
- Spine segment faces commoditization pressure from multiple competitors
Compare more than two at a time
This page is a fixed writeup on SNN and ZBH. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside SNN and ZBH, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.